Format
Sort by

Send to:

Choose Destination

Results: 5

Related Articles by Review for PubMed (Select 18441205)

1.

Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, Nithipatikom K.

Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2838-44. doi: 10.1152/ajpheart.00186.2008. Epub 2008 Apr 25.

2.

Soluble epoxide hydrolase: a new target for cardioprotection.

Gross GJ, Nithipatikom K.

Curr Opin Investig Drugs. 2009 Mar;10(3):253-8. Review.

3.

Epoxyeicosatrienoic acids and cardioprotection: the road to translation.

Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM.

J Mol Cell Cardiol. 2014 Sep;74:199-208. doi: 10.1016/j.yjmcc.2014.05.016. Epub 2014 Jun 2. Review.

PMID:
24893205
4.

Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):50-9. Epub 2006 Jul 10. Review.

5.

Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs).

Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):42-9. Epub 2006 Jul 5. Review.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk